Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose of selumetinib and how well it works with
durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer
or that has come back. Immunotherapy with monoclonal antibodies, such as durvalumab and
tremelimumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Selumetinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving durvalumab, tremelimumab and
selumetinib may work better in treating participants with non-small lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Ipilimumab Tremelimumab